Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EDNRB | P24530 | 17/20 | 0.60 |
| ▸ | EDNRA | P25101 | 17/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233059 | 0.90 | KMT2A (0.63) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7233099 | 0.84 | EDNRB (0.67) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7231537 | 0.83 | EDNRB (0.65) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7230220 | 0.83 | EDNRB (0.64) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7230496 | 0.80 | EDNRB (0.61) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7230471 | 0.80 | EDNRB (0.61) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7230914 | 0.79 | EDNRB (0.66) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7230939 | 0.79 | EDNRB (0.66) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7238239 | 0.79 | EDNRB (0.71) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL7237426 | 0.79 | EDNRB (0.68) | KMT2AEDNRBEDNRANR1I2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509341-B1 | The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the meaning as commented in the description. It also relates to the production and use of same as endothelin receptor antagonists. | ABBOTT LABORATORIES | 2003-01-21 | — | — | US | disclosed |